CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: DLEU2 (ImmuneEditome ID:8847)

1. Gene summary of enriched editing regions for DLEU2

check button Gene summary
Gene informationGene symbol

DLEU2

Gene ID

8847

GeneSynonymsALT1|BCMSUN|DLB2|LEU2|LINC00022|MIR15AHG|NCRNA00022|RFP2|RFP2OS|TRIM13OS
GeneCytomap

13q14.2

GeneTypencRNA
GeneDescriptiondeleted in lymphocytic leukemia 2 (non-protein coding)|leukemia associated gene 2|long intergenic non-protein coding RNA 22|mir-15a-16-1 cluster host gene (non-protein coding)|ret finger protein 2 opposite strand
GeneModificationdate20230329
UniprotID.
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr13:49986243-49986831:-ENST00000621282.3ENSG00000231607.7DLEU2ncRNA_intronicAluSx,AluSx4chr13:49986243-49986831:-.alignment
chr13:49990187-49991379:-ENST00000621282.3ENSG00000231607.7DLEU2ncRNA_intronicAluJb,AluSx1,AluSpchr13:49990187-49991379:-.alignment
chr13:49994731-49995425:-ENST00000621282.3ENSG00000231607.7DLEU2ncRNA_intronicAluJo,AluSxchr13:49994731-49995425:-.alignment
chr13:50021014-50024552:-ENST00000621282.3ENSG00000231607.7DLEU2ncRNA_intronicAluSx1,(AAC)n,AluSx3,AluSx,AluJo,FLAM_C,AluJr,AluScchr13:50021014-50024552:-.alignment
chr13:50035301-50035534:-ENST00000425586.4ENSG00000231607.7DLEU2ncRNA_intronicAluSxchr13:50035301-50035534:-.alignment
chr13:50035301-50035534:-ENST00000621282.3ENSG00000231607.7DLEU2ncRNA_intronicAluSxchr13:50035301-50035534:-.alignment
chr13:50037353-50039953:-ENST00000425586.4ENSG00000231607.7DLEU2ncRNA_intronicL3,AluSx3,AluJo,AluSxchr13:50037353-50039953:-.alignment
chr13:50037353-50039953:-ENST00000621282.3ENSG00000231607.7DLEU2ncRNA_intronicL3,AluSx3,AluJo,AluSxchr13:50037353-50039953:-.alignment
chr13:50042001-50042235:-ENST00000425586.4ENSG00000231607.7DLEU2ncRNA_intronicAluSgchr13:50042001-50042235:-.alignment
chr13:50042001-50042235:-ENST00000621282.3ENSG00000231607.7DLEU2ncRNA_intronicAluSgchr13:50042001-50042235:-.alignment
chr13:50047373-50047818:-ENST00000235290.6ENSG00000231607.7DLEU2ncRNA_intronicAluSq2,(ATTTTA)n,AluJo,AluYchr13:50047373-50047818:-.alignment
chr13:50047373-50047818:-ENST00000425586.4ENSG00000231607.7DLEU2ncRNA_intronicAluSq2,(ATTTTA)n,AluJo,AluYchr13:50047373-50047818:-.alignment
chr13:50047373-50047818:-ENST00000433070.5ENSG00000231607.7DLEU2ncRNA_intronicAluSq2,(ATTTTA)n,AluJo,AluYchr13:50047373-50047818:-.alignment
chr13:50047373-50047818:-ENST00000443587.4ENSG00000231607.7DLEU2ncRNA_intronicAluSq2,(ATTTTA)n,AluJo,AluYchr13:50047373-50047818:-.alignment
chr13:50047373-50047818:-ENST00000458725.4ENSG00000231607.7DLEU2ncRNA_intronicAluSq2,(ATTTTA)n,AluJo,AluYchr13:50047373-50047818:-.alignment
chr13:50047373-50047818:-ENST00000621282.3ENSG00000231607.7DLEU2ncRNA_intronicAluSq2,(ATTTTA)n,AluJo,AluYchr13:50047373-50047818:-.alignment
chr13:50050058-50050703:-ENST00000235290.6ENSG00000231607.7DLEU2ncRNA_intronicAluJr,(T)nchr13:50050058-50050703:-.alignment
chr13:50050058-50050703:-ENST00000421758.4ENSG00000231607.7DLEU2ncRNA_intronicAluJr,(T)nchr13:50050058-50050703:-.alignment
chr13:50050058-50050703:-ENST00000425586.4ENSG00000231607.7DLEU2ncRNA_intronicAluJr,(T)nchr13:50050058-50050703:-.alignment
chr13:50050058-50050703:-ENST00000433070.5ENSG00000231607.7DLEU2ncRNA_intronicAluJr,(T)nchr13:50050058-50050703:-.alignment
chr13:50050058-50050703:-ENST00000443587.4ENSG00000231607.7DLEU2ncRNA_intronicAluJr,(T)nchr13:50050058-50050703:-.alignment
chr13:50050058-50050703:-ENST00000449579.1ENSG00000231607.7DLEU2ncRNA_intronicAluJr,(T)nchr13:50050058-50050703:-.alignment
chr13:50050058-50050703:-ENST00000458725.4ENSG00000231607.7DLEU2ncRNA_intronicAluJr,(T)nchr13:50050058-50050703:-.alignment
chr13:50050058-50050703:-ENST00000621282.3ENSG00000231607.7DLEU2ncRNA_intronicAluJr,(T)nchr13:50050058-50050703:-.alignment
chr13:50064938-50065674:-ENST00000235290.6ENSG00000231607.7DLEU2ncRNA_intronicAluSp,(TA)n,AluYh3chr13:50064938-50065674:-.alignment
chr13:50064938-50065674:-ENST00000421758.4ENSG00000231607.7DLEU2ncRNA_intronicAluSp,(TA)n,AluYh3chr13:50064938-50065674:-.alignment
chr13:50064938-50065674:-ENST00000425586.4ENSG00000231607.7DLEU2ncRNA_intronicAluSp,(TA)n,AluYh3chr13:50064938-50065674:-.alignment
chr13:50064938-50065674:-ENST00000433070.5ENSG00000231607.7DLEU2ncRNA_intronicAluSp,(TA)n,AluYh3chr13:50064938-50065674:-.alignment
chr13:50064938-50065674:-ENST00000443587.4ENSG00000231607.7DLEU2ncRNA_intronicAluSp,(TA)n,AluYh3chr13:50064938-50065674:-.alignment
chr13:50064938-50065674:-ENST00000449579.1ENSG00000231607.7DLEU2ncRNA_intronicAluSp,(TA)n,AluYh3chr13:50064938-50065674:-.alignment
chr13:50064938-50065674:-ENST00000458725.4ENSG00000231607.7DLEU2ncRNA_intronicAluSp,(TA)n,AluYh3chr13:50064938-50065674:-.alignment
chr13:50064938-50065674:-ENST00000621282.3ENSG00000231607.7DLEU2ncRNA_intronicAluSp,(TA)n,AluYh3chr13:50064938-50065674:-.alignment


Top

2. Tumor-specific enriched editing regions for DLEU2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for DLEU2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for DLEU2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for DLEU2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr13:50037353-50039953:-BRCAEERT_cells_follicular_helper3.8561e-020.3861image
ENSG00000231607.7,DLEU2BRCAEAGMacrophages_M11.7614e-020.2040image
ENSG00000231607.7,DLEU2CESCEAGMacrophages_M02.0144e-020.3071image
ENSG00000231607.7,DLEU2COADEAGT_cells_regulatory_(Tregs)4.4643e-020.4134image
chr13:49990187-49991379:-ESCAEERB_cells_memory4.0679e-020.3582image
chr13:50064938-50065674:-ESCAEERDendritic_cells_resting6.1960e-030.3197image
ENSG00000231607.7,DLEU2ESCAEAGT_cells_CD4_memory_activated1.4330e-030.2758image
chr13:49994731-49995425:-GBMEERT_cells_CD4_memory_activated1.9446e-020.4552image
chr13:50021014-50024552:-LAMLEERMacrophages_M25.5867e-030.3688image
chr13:50037353-50039953:-LAMLEERT_cells_follicular_helper1.9138e-020.2522image
ENSG00000231607.7,DLEU2LAMLEAGT_cells_CD4_memory_activated2.5888e-020.2034image
chr13:49990187-49991379:-LGGEERT_cells_CD4_memory_activated1.0982e-020.3717image
ENSG00000231607.7,DLEU2LGGEAGT_cells_CD4_memory_activated6.5756e-030.3265image
ENSG00000231607.7,DLEU2LUADEAGDendritic_cells_activated5.9410e-030.4082image
ENSG00000231607.7,DLEU2LUSCEAGNK_cells_activated7.6263e-040.5896image
chr13:49990187-49991379:-OVEERNK_cells_activated3.9602e-02-0.3398image
chr13:49990187-49991379:-PCPGEERT_cells_CD4_memory_activated3.3617e-020.2952image
chr13:50037353-50039953:-STADEERNK_cells_resting6.7024e-030.2109image
chr13:50047373-50047818:-STADEERB_cells_memory1.0247e-02-0.2636image
chr13:50064938-50065674:-STADEERT_cells_CD4_memory_activated7.2677e-030.2206image
ENSG00000231607.7,DLEU2STADEAGT_cells_CD4_memory_resting2.4855e-020.1454image
ENSG00000231607.7,DLEU2THCAEAGB_cells_memory2.5643e-02-0.1921image
chr13:49990187-49991379:-THYMEERT_cells_gamma_delta2.0498e-020.3698image


Top

6. Enriched editing regions and immune gene sets for DLEU2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr13:50047373-50047818:-STADEER8.6626e-030.26934.0309e-020.21195.4175e-040.35012.6788e-020.2284image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000231607.7,DLEU2BRCAGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.9233e-040.3156image
chr13:50037353-50039953:-BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER8.5898e-030.4788image
ENSG00000231607.7,DLEU2CESCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.0372e-020.2871image
chr13:49990187-49991379:-CESCGSVA_HALLMARK_HYPOXIAEER5.3143e-030.5730image
ENSG00000231607.7,DLEU2COADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG2.8567e-040.6763image
ENSG00000231607.7,DLEU2ESCAGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG2.3749e-020.1975image
chr13:50037353-50039953:-ESCAGSVA_HALLMARK_PROTEIN_SECRETIONEER3.2008e-040.3651image
chr13:49994731-49995425:-ESCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER5.4138e-040.4514image
chr13:50064938-50065674:-ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.7295e-040.4285image
chr13:49990187-49991379:-ESCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.2805e-020.3953image
chr13:49994731-49995425:-GBMGSVA_HALLMARK_COMPLEMENTEER4.4332e-030.5397image
chr13:49990187-49991379:-GBMGSVA_HALLMARK_MITOTIC_SPINDLEEER4.5270e-02-0.2762image
chr13:49990187-49991379:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.9360e-020.3720image
chr13:50021014-50024552:-LAMLGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.6101e-02-0.2999image
chr13:50035301-50035534:-LAMLGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER8.1178e-03-0.5076image
chr13:50037353-50039953:-LAMLGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.0046e-020.2762image
ENSG00000231607.7,DLEU2LUADGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.8604e-020.3130image
ENSG00000231607.7,DLEU2LUSCGSVA_HALLMARK_MTORC1_SIGNALINGEAG3.0485e-02-0.4023image
chr13:50037353-50039953:-OVGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.7281e-020.2409image
chr13:49990187-49991379:-OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.1597e-020.3540image
ENSG00000231607.7,DLEU2OVGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.3832e-050.3246image
ENSG00000231607.7,DLEU2PCPGGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.3443e-020.2709image
ENSG00000231607.7,DLEU2SARCGSVA_HALLMARK_UV_RESPONSE_DNEAG3.8995e-030.4754image
chr13:50037353-50039953:-STADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER4.0779e-040.2729image
ENSG00000231607.7,DLEU2STADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG1.7962e-070.3305image
chr13:49994731-49995425:-STADGSVA_HALLMARK_COAGULATIONEER4.1600e-020.2284image
chr13:49990187-49991379:-STADGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.2315e-030.4401image
chr13:50047373-50047818:-STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER9.6144e-030.2658image
ENSG00000231607.7,DLEU2THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.7101e-050.3528image
chr13:49990187-49991379:-THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER5.9827e-030.2496image


Top

7. Enriched editing regions and drugs for DLEU2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000231607.7,DLEU2BRCAElesclomolEAG1.4510e-03-0.2714image
chr13:49990187-49991379:-BRCACI.1040EER3.8534e-03-0.3904image
chr13:49990187-49991379:-CESCBryostatin.1EER4.0194e-03-0.5878image
ENSG00000231607.7,DLEU2CESCFTI.277EAG2.8830e-02-0.2897image
ENSG00000231607.7,DLEU2COADBI.D1870EAG3.3375e-02-0.4356image
chr13:49990187-49991379:-ESCABleomycinEER2.0968e-02-0.4003image
ENSG00000231607.7,DLEU2ESCABexaroteneEAG2.8034e-02-0.1920image
chr13:50037353-50039953:-ESCACamptothecinEER9.7506e-040.3365image
chr13:50042001-50042235:-ESCAAxitinibEER2.3796e-020.4598image
chr13:49994731-49995425:-ESCABI.D1870EER7.0860e-03-0.3591image
chr13:50064938-50065674:-ESCABX.795EER9.1825e-04-0.3823image
chr13:49994731-49995425:-GBMDMOGEER1.4841e-02-0.4723image
chr13:49990187-49991379:-GBMAZD.0530EER3.2343e-020.2944image
chr13:50037353-50039953:-LAMLAICAREER2.9908e-02-0.2343image
chr13:50050058-50050703:-LAMLAP.24534EER2.8737e-02-0.4290image
chr13:50035301-50035534:-LAMLFH535EER3.4661e-04-0.6478image
chr13:49990187-49991379:-LUADBMS.754807EER1.8997e-02-0.5070image
ENSG00000231607.7,DLEU2LUADATRAEAG3.8187e-020.3136image
ENSG00000231607.7,DLEU2LUSCGemcitabineEAG4.7658e-040.6073image
chr13:50037353-50039953:-OVCamptothecinEER1.0094e-020.2793image
chr13:49994731-49995425:-OVBexaroteneEER6.9021e-030.2860image
chr13:49990187-49991379:-OVAZD6244EER8.1412e-030.4285image
ENSG00000231607.7,DLEU2OVBI.D1870EAG7.0682e-040.2744image
chr13:49990187-49991379:-PCPGGSK269962AEER2.8433e-02-0.3040image
ENSG00000231607.7,DLEU2PCPGGW.441756EAG4.8982e-02-0.2643image
ENSG00000231607.7,DLEU2SARCAZD6482EAG4.4814e-03-0.4690image
chr13:50037353-50039953:-STADATRAEER2.5307e-030.2343image
chr13:50021014-50024552:-STADIPA.3EER2.1500e-02-0.3458image
ENSG00000231607.7,DLEU2STADGemcitabineEAG8.8375e-050.2514image
chr13:50064938-50065674:-STADAICAREER2.9726e-020.1794image
chr13:49994731-49995425:-STADCCT018159EER1.4934e-02-0.2713image
chr13:49990187-49991379:-STADEtoposideEER3.4991e-030.4015image
chr13:50047373-50047818:-STADAG.014699EER4.9564e-040.3524image
chr13:49990187-49991379:-THCABicalutamideEER1.6608e-02-0.2183image
ENSG00000231607.7,DLEU2THCALapatinibEAG2.7678e-03-0.2556image
chr13:49990187-49991379:-THYMA.770041EER1.9398e-020.3729image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType